Abstract
In January, the Food and Drug Administration (FDA) issued guidance permitting pharmaceutical and device manufacturers to distribute reprints of articles from medical journals that discuss the off-label use of products. The authors review the history of FDA regulation of off-label promotion and discuss the pertinent legal and policy issues.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
